Beta 3 agonist treatment in heart failure (BEAT-HF)

The Heart Center, Rigshospitalet0 sites85 target enrollmentMay 28, 2013

Overview

No summary available.

Registry

who.int

Start Date

May 28, 2013

End Date

TBD

Last Updated

10 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

The Heart Center, Rigshospitalet

•Inclusion criteria
•1\.Stable heart failure NYHA class II\-III on ischemic or non\-ischemic basis
•2\.Left ventricular ejection fraction (LVEF) \< 40%
•3\.Stable sinus rhythm (SR)
•4\.On optimised evidence\-based pharmacological HF treatment stable \> 4 weeks with no current plan for changing HF therapy. The therapy must include a beta\-blocker.
•5\.No change in diuretics \< 4 weeks
•6\.\>18 years
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) no

•Exclusion criteria
•1\.Unstable cardiac condition
•2\.Acute myocardial infarction (AMI) or revascularisation \< 3 month ago
•3\.Atrial fibrillation (for technical reasons in relation to imaging and HR reporting)
•4\.Uncorrected significant primary obstructive valve disease
•5\.Planned major surgery including cardiac revascularisation
•6\.Hemodynamically significant obstructive cardiomyopathy
•7\.Stroke with significant neurological deficit
•8\.Acute myocarditis or constrictive pericarditis
•9\.Symptomatic bradycardia or \> 1\. degree AV\-block unless the patient has a pacemaker